Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003931 · ClinicalTrials.gov registry record
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 9,769
- Enrollment target
NCT00003931 is a clinical trial that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 9,769 participants.
The verdict
NCT00003931 has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 9,769 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia.
Interventions
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,769 participants |
| Start Date | 1999-02 |
| Est. Completion | 2006-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003931
The ClinicalTrials.gov registry entry for NCT00003931 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,769 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which reverse transcriptase-polymerase chain reaction is the first listed.
NCT00003931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003931 about?
NCT00003931 is a clinical study titled "Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia". RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia.
What is the current status of trial NCT00003931?
This trial is currently completed. The enrollment target is 9,769 participants. The study started on 1999-02. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00003931?
The interventions under investigation include: reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT00003931?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.